Prescription Digital Therapeutics - (0565) — MM 0565 | CIGNA Coverage Update

Cigna modified MM 0565 covering prescription digital therapeutics, effective December 16, 2025. Three HCPCS codes — E0738, E0739, and E1905 — are now explicitly classified as experimental, investigational, and unproven under this policy. Here's what your billing team needs to do before claims hit the clearinghouse.

Cigna Healthcare updated its prescription digital therapeutics coverage policy under MM 0565 in December 2025. The policy draws a hard line between FDA-approved, peer-reviewed PDTs and general wellness software — and the three HCPCS codes in scope all land on the wrong side of that line. If your practice bills for upper extremity rehab systems or virtual reality CBT devices, this change creates direct claim denial risk starting December 16, 2025.

Quick-Reference Table

Cigna Prescription Digital Therapeutics Coverage Criteria and Medical Necessity Requirements 2025

The Cigna prescription digital therapeutics coverage policy under MM 0565 sets a three-part test for what qualifies as a covered PDT. The service must require a prescription from a healthcare provider. It must be FDA-approved. And its safety and effectiveness must be supported by published, peer-reviewed clinical evidence for treating, managing, or preventing a disease or disorder.

That third criterion is where most of the action is. Peer-reviewed evidence supporting disease treatment is a higher bar than FDA clearance alone. A device can clear FDA's 510(k) pathway without randomized controlled trial data. Cigna is not treating FDA clearance as sufficient for coverage — medical necessity under this policy requires clinical evidence that the PDT actually treats disease.

The policy also defines what doesn't qualify. Software used for general health promotion, wellness, or fitness is not a PDT under MM 0565. Neither is software used solely to inform, monitor, or diagnose — those functions don't treat disease, so they don't meet the coverage policy definition. Over-the-counter digital therapeutics — those that don't require a prescription — are excluded from this policy entirely and fall to individual benefit determination.

This is an important distinction for billing. The Cigna prescription digital therapeutics billing guidelines aren't about whether a product has a HCPCS code. They're about whether the product clears all three criteria: prescription required, FDA-approved, peer-reviewed disease treatment evidence. If any one of those is missing, the claim won't survive review.

Prior authorization requirements for specific PDTs under MM 0565 are not detailed in the current policy text. But given that all three HCPCS codes in scope are currently classified as experimental, prior auth won't save a denied claim — Cigna's position is that these services aren't covered at all in their current classification. Talk to your Cigna provider relations contact if you believe a specific product has changed its FDA or evidence status since this policy was written.

Cigna Prescription Digital Therapeutics Exclusions and Non-Covered Indications

This is the section that matters most for reimbursement right now. All three HCPCS codes addressed in MM 0565 carry the same classification: experimental, investigational, and unproven.

E0738 covers upper extremity rehabilitation systems that provide active assistance to facilitate muscle re-education. Think powered or robotic-assisted arm rehab devices that are software-driven and delivered as a digital therapeutic.

E0739 covers rehabilitation systems with an interactive interface providing active assistance in rehabilitation therapy. This is a broader category — interactive software-guided rehab that actively assists patient movement during therapy sessions.

E1905 covers virtual reality cognitive behavioral therapy devices, including preprogrammed therapy software. VR-CBT has gotten a lot of attention in behavioral health and pain management circles. Cigna's position is clear: not covered.

The real issue here is that all three of these codes sit in a product category that has been commercially active and heavily marketed to practices and patients. Some vendors have sold these solutions with implied reimbursement potential. MM 0565 makes Cigna's answer explicit — these are not covered services under the current evidence standard. Practices that have been billing these codes to Cigna need to stop immediately and audit any outstanding claims.

Coverage Indications at a Glance

Cigna Prescription Digital Therapeutics Billing Guidelines and Action Items 2025

CPT, HCPCS, and ICD-10 Codes for Prescription Digital Therapeutics Under MM 0565

Not Covered / Experimental Codes Under MM 0565

All three HCPCS codes addressed in this policy are classified as experimental, investigational, and unproven by Cigna Healthcare. There are no covered codes listed in the current MM 0565 policy update.

No ICD-10 codes are specified in the MM 0565 policy data. The policy's coverage criteria apply at the product/service level, not by diagnosis.

No covered CPT or HCPCS codes are listed in the current policy update. The policy describes criteria that a PDT would need to meet for coverage consideration, but does not enumerate specific covered codes. If you're billing a PDT product not captured by E0738, E0739, or E1905, confirm its coding with the manufacturer and verify Cigna's current position through your provider portal or a coverage determination request.